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Grainyhead-like 2 is expressed in 
the distal nephron and regulates the 
composition of epithelial junctions
Werth et al., Development 2010; 137: 3835–3845; doi:10.1242/dev.055483
The multiple cell types and distinct functional domains in the 
nephron are in great part the result of distinct apical junctional 
complexes, which include adherens junctions (where cadherins 
locate) and tight junctions (where claudins predominate). These 
complexes are nephron segment-specific, as they regulate cell iden-
tity, the interaction of the cellular interior with its neighbors, and 
the barrier and transport properties of the different segments. For 
example, the proximal tubule is a ‘leaky epithelium’ that carries 
out ions and water at a high rate but is unable to maintain steep 
osmotic and electrical gradients. In contrast, the collecting duct is 
a ‘tight epithelium,’ capable of maintaining steep osmotic gradi-
ents. While N-cadherin and claudin 2 predominate in the proximal 
tubule, E-cadherin and claudin 4 predominate in the collecting 
duct and where expression of this claudin increases in response 
to hyperosmolality. Thus, mechanisms that determine the iden-
tity of junction complexes along the nephron are of great interest. 
To identify such regulators, Werth et al. did microarray assays of 
an epithelial cell line and of epithelia from the early embryonic 
kidney. Of several transcription factors identified, they focused 
on grainyhead-like 2 (Grhl2), as members of this family had been 
implicated in regulation of epithelial junctional components. They 
found that Grhl2 was highly expressed in the ureteric bud of the 
developing kidney, where it colocalized with E-cadherin. In addi-
tion, Grhl2 was expressed in the developing distal tubule (but not 
in glomerular or proximal nephron epithelia), and its expression 
was maintained in the distal nephron of the adult kidney (Fig-
ure). The authors generated Grhl2 mutant mice and found that 
embryos had defective epithelial differentiation and neural tube 
defects as well as reduced E-cadherin and claudin 4 expression. 
Moreover, in vitro work showed that Grhl2 specifically associated 
with DNA motifs in the promoter of the claudin 4 gene and in the 
second intron of the E-cadherin gene, and thereby regulated their 
expression levels.
Because mutant mice died before kidney development, the 
exact role of Grhl2 in determining junctional complexes along 
the nephron must await the generation of conditional or kidney-
specific genetic mutants. However, this elegant study reveals a 
critical role of Grhl2 in regulating the composition of epithelial 
junctions and thereby epithelial differentiation.
Juan Oliver
Local regulation of arterial calcium 
entry by reactive oxygen species
Amberg et al., Circ Res 2010; 107: 1002–1010; doi:10.1161/
CIRCRESAHA.110.217018
Oxidation and reduction reactions are integral components of 
cellular biology, but disruptions of cellular redox states beyond 
physiological parameters are associated with a variety of diseases. 
Indeed, generation of reactive oxygen species (ROS) with increased 
oxidative stress has been implicated in the vascular effects of angi-
otensin II and high-salt diet, and in the pathogenesis of hyperten-
sion. However, the mechanisms that transduce changes in redox 
signaling to changes in cellular processes that affect function are 
poorly understood. Peripheral arterial tone (that is, peripheral vas-
cular resistance) is determined by the contractile state of arterial 
smooth muscle, which is, in turn, tightly coupled to Ca2+ influx 
through L-type voltage-dependent CaV1.2 Ca2+ channels. In turn, 
this channel’s activity is regulated by protein kinase Cα (PKCα), 
and this enzyme is necessary for normal arterial function. In a 
recent report, Amberg et al. examined whether ROS may regulate 
L-type Ca2+ channel activity in arterial smooth muscle cells. To do 
this, they used total internal reflection fluorescence (TIRF) micros-
copy and examined L-type Ca2+ channel activity. TIRF microscopy 
allows detection of fluorescence signals in very thin regions of a cell 
(or even of a single molecule), and thus, changes in channel activ-
ity (Ca2+ influx) can be detected with high temporal and spatial 
resolution. In isolated cerebral arterial smooth muscle cells, the 
authors found highly localized subplasmalemmal generation of 
endogenous ROS, which preceded and colocalized with sites of 
enhanced L-type Ca2+ channel activity. Further, exogenous ROS 
increased localized L-type Ca2+ channel activity in isolated arte-
rial myocytes via activation of PKCα, and, when applied to intact 
cerebral arterial segments, exogenous ROS increased arterial tone 
in an L-type Ca2+ channel-dependent fashion. Angiotensin is well 
known to stimulate ROS-generating NADPH oxidase, and Amberg 
et al. found that angiotensin II-dependent stimulation of L-type 
Ca2+ channel activity in isolated cells and contraction of intact 
arteries were abolished following inhibition of NADPH oxidase.
This study suggests a novel model of local oxidative regulation 
of Ca2+ influx where vasoconstrictors coupled to NADPH oxidase 
(for instance, angiotensin II) induce discrete sites of ROS genera-
tion, resulting in oxidative activation of adjacent PKCα molecules 
that, in turn, promote local sites of enhanced L-type Ca2+ channel 
activity, resulting in increased Ca2+ influx and contraction. These 
Expression of Grhl2 in the distal nephron of the adult kidney. Grhl2 
colocalized with cells containing the Na-Cl cotransporter (Ncc, distal tubule, 
top) and cells containing aquaporin 2 (Aqp2, collecting duct, bottom).
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results suggest intriguing research avenues to clarify the role of 
ROS in hypertension and other vascular and renal diseases.
Juan Oliver
Low glomerular filtration rate  
and risk of stroke: meta-analysis
Lee et al., BMJ 2010; 341: c4249; doi:10.1136/bmj.c4249
Chronic kidney disease and cardiovascular disease are major pub-
lic-health problems worldwide and often share the same patho-
physiological mechanisms. A recent meta-analysis showed that 
an estimated glomerular filtration rate (eGFR) less than 60 ml/
min/1.73 m2 was associated with all-cause and cardiovascular mor-
tality in the general population.1 The effect of reduced eGFR on 
incident stroke, however, has not been well delineated in a qualita-
tive or quantitative manner using the totality of published data. Lee 
and colleagues carried out a systematic review and meta-analysis to 
determine whether a link exists between reduced eGFR and inci-
dent stroke, using 21 articles derived from 33 prospective studies: 
14 articles assessed eGFR <60 ml/min/1.73 m2 and seven assessed 
eGFR at both <60 ml/min/1.73 m2 and 60–90 ml/min/1.73 m2, for 
a total of 284,672 participants (follow-up 3.2–15 years) with 7863 
stroke events. Incident stroke risk increased among participants 
with an eGFR <60 ml/min/1.73 m2 (relative risk (RR) 1.43, 95% 
confidence interval (CI) 1.31–1.57) but not among those with an 
eGFR of 60–90 ml/min/1.73 m2 (RR 1.07, 95% CI 0.98–1.17). Sig-
nificant heterogeneity existed between estimates among patients 
with an eGFR <60 ml/min/1.73 m2. In subgroup analyses among 
participants with an eGFR <60 ml/min/1.73 m2, heterogeneity was 
significant in Asians compared with non-Asians (RR 1.96, 95% CI 
1.73–2.23, versus RR 1.25, 95% CI 1.16–1.35), and in those with an 
eGFR of 40–60 ml/min/1.73 m2 compared with <40 ml/min/1.73 
m2 (RR 1.28, 95% CI 1.04–1.56, versus RR 1.77, 95% CI 1.32–2.38). 
This study adds the following new data: People with a baseline eGFR 
<60 ml/min/1.73 m2 had an independent risk of future stroke that 
was 43% greater than that of people with a normal baseline eGFR. 
A dose–response relation between eGFR <60 ml/min/1.73 m2 and 
risk of stroke was observed, with risk of stroke being significantly 
greater for levels <40 ml/min/1.73 m2 compared with 40–60 ml/
min/1.73 m2. Asian patients with an eGFR <60 ml/min/1.73 m2 
were at higher risk of stroke than people of non-Asian ethnicity.
This well-performed study suffers to a certain extent from the 
classic meta-analysis biases: the difficulty of identifying all relevant 
studies, the varying quality of the studies, and the heterogeneity 
of the study results. Despite these limitations, the results of this 
systematic review represent the most precise and accurate estimate 
currently available of the strength of the relation between reduced 
eGFR and incident stroke.
Marc De Broe
1Lancet 2010; 375: 2073–2081.
Rolofylline, an adenosine 
A1-receptor antagonist,  
in acute heart failure
Massie et al., N Engl J Med 2010; 363: 1419–1428; doi:10.1056/
NEJMoa0912613
Adenosine has been suggested as a mediator of the counterrregula-
tory responses of decreased kidney function in worsening heart 
failure. A multicenter, placebo-controlled trial randomized 2033 
patients hospitalized for heart failure to receive daily intravenous 
rolofylline (an adenosine A1-receptor antagonist) or placebo for 
up to 3 days. Eligible patients had persistent dyspnea at rest or with 
minimal activity, a creatinine clearance between 20 and 80 ml/min, 
an elevated brain natriuretic peptide level, and ongoing intrave-
nous loop-diuretic therapy. The primary end point was patient-
reported moderate or marked improvement in dyspnea at 24 and 
48 hours after drug treatment. Subjects in the two treatment arms 
were similar. The average age in both groups was 70.2 years, and 
the average creatinine clearance was approximately 50 cc/min at 
baseline. The percentages of subjects reporting an improvement 
in symptoms were 40.6% and 36.0%, and the percentages of sub-
jects reporting no change in symptoms were 37.5% and 44.2%, 
in the rolofylline and placebo groups, respectively. However, the 
percentages of subjects who reported worsening of symptoms or 
who experienced death, readmission for heart failure within a 
week, or persistently worsening renal function were 21.8% and 
19.8%. These differences resulted in an odds ratio for the primary 
outcome of 0.92 (95% CI 0.78–1.09).
This large trial with relatively neutral results provides the impor-
tant lesson that caution is needed in the interpretation of earlier-
phase trials. The pilot study for this trial randomized 301 patients 
to rolofylline or placebo and demonstrated improvement in dys-
pnea of 59.4% and 41.3% in the rolofylline and placebo groups, 
respectively, with a lower likelihood of experiencing renal impair-
ment (8.0% versus 18.2%). Subjects receiving rolofylline also had 
a trend toward a lower 60-day rate of death or readmission for 
cardiovascular or renal causes (hazard ratio 0.55, 95% CI 0.28–
1.04). This difference underscores the utility of the clinical devel-
opment process for the approval of new medications and tempers 
the enthusiasm generated by small, positive studies with a higher 
likelihood of type I statistical error.
Lynda Szczech 
 Proposed mechanism by which local generation of ROS stimulates PKC-
dependent L-type Ca2+ channel activity in smooth muscle cells. Ang II, 
angiotensin II; AT1R, angiotensin II type 1 receptor.
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